Enlivex ( (ENLV) ) has provided an announcement.
Enlivex Therapeutics announced on March 17, 2025, that the China National Intellectual Property Administration has issued a notice of allowance for a patent application related to the use of Allocetra™ in treating osteoarthritis, providing intellectual property protection in China through at least 2040. This development follows positive interim results from a Phase I/II trial showing significant pain reduction and improved joint function in osteoarthritis patients, with no serious adverse events reported, enhancing Enlivex’s market positioning and potential stakeholder confidence.
More about Enlivex
Enlivex Therapeutics Ltd. is a clinical-stage company specializing in macrophage reprogramming immunotherapy. The company is developing Allocetra™, a universal, off-the-shelf cell therapy aimed at reprogramming macrophages into their homeostatic state to address life-threatening and debilitating conditions.
YTD Price Performance: -1.61%
Average Trading Volume: 138,204
Technical Sentiment Consensus Rating: Buy
Current Market Cap: $26.83M
For an in-depth examination of ENLV stock, go to TipRanks’ Stock Analysis page.